| Name | Title | Contact Details |
|---|
Founded by Chief Executive Officer Sam Solakyan, Global Holdings, Inc. has excelled in its journey in becoming leaders in each of the industries it has a presence in. Their main responsibility lies in providing their clients with the most premiere level of service. More than just your typical holdings group, Global is a multifaceted company with financial assets and ownership in the radiology, pharmaceuticals, and medical billing and collections industries. Instead of merely buying and selling companies like other holdings groups, Global searches for the less desirable companies with hidden potential and applies its knowledge and expertise in the management field and aids in the recreation of a company that once was not.
Capital Rx is built around the mission of changing the way prescription drugs are priced and patients are serviced. A health technology company daring to reimagine the pharmacy benefits industry, Capital Rx is executing on that mission through its Clearinghouse Model® - the first ethical framework for drug pricing. Capital Rx`s enterprise pharmacy platform, JUDI™, connects every aspect of the pharmacy ecosystem in one platform, enabling patient engagement, and increasing efficiency to achieve the highest standards of clinical care.
Tympany, LLC is a Spring, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AstraZeneca is a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialisation of primary care and speciality care medicines. We believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines. We invest in distinctive science in three main therapy areas where we believe we can make the most meaningful difference to patients: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity. Our science exploits our rare combination of capabilities in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalised healthcare capabilities. We build on our own capabilities by collaborating with world-renowned scientists and academic institutions and partnering with like-minded science-led companies. Through leading in science, we are confident that we can transform the lives of people around the world and deliver value to our shareholders.
We are dedicated to quality service for the medically fragile child. We service our patients based on each child's specific needs to develop their potential through clinical education and technical support. We believe it takes more than health care to